Dr. Conrad Savoy has been Chief Executive Officer and President of BioPartners GmbH since May 2009. Dr. Savoy serves as the Chief Executive Officer of Obexia AG. Dr. Savoy served as Chief Scientific Officer of BioPartners GmbH since May 2007. He served as the Head of Pharma Development (hGH) of BioPartners GmbH since 2001. Dr. Savoy has a wealth of experience in the global development of pharmaceutical products, which he gained during the many years he spent with Hoffmann-La Roche prior to joining BioPartners. During his time with Roche, he served as its Global Regulatory Affairs Manager in which he was responsible for the development and implementation of the regulatory strategies for numerous novel chemical entities at various stages of clinical and technical development. Dr. Savoy has substantial experience of global regulatory authorities including the FDA and EMEA and has managed several projects reliant on the centralized European approval procedure. He has also led drug development teams responsible for CPMP hearings as well as FDA Advisory Board meetings. This notable experience puts him in an excellent position to successfully lead the clinical and technical development of BioPartners’ biopharmaceuticals portfolio, in particular the global approval of BioPartners’ sustained release human growth hormone preparation. He serves as Director of BioPartners GmbH and Board Member of Obexia AG. Dr. Savoy also has a sound academic background including an MBA which he gained from Open University Business School, UK and a PhD from the University of Basel, Switzerland.

Development and implementation of the regulatory strategies